DOGWOOD THERAPEUTICS INC (DWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.04+0.97%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · DWTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
DWTX — private placement
Dated 2026-10-19
Entry into a Material Definitive Agreement. Subscription Agreement On October 19, 2026, Dogwood Therapeutics, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with Sealbond Limited (“Sealbond”), pursuant to which the Company agreed to issue and sell 4,098,360 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company to Sealbond in a private placement. The Shares are being sold at a purchase price of $1.22 p…
Why it matters: The company said cash would last through its Phase 2b readout. The new financing is meant to fund Phase 3 work and extend runway through March 2027.
Worry ifA company filing confirms the placement closed. Dogwood reports cash to last through March 2027 or later.
Less concerning ifThe placement fails to close, or Dogwood reports runway ending before March 2027.
Why it matters: The company has begun Phase 3 planning. A clear plan after the data would show what comes next for its lead drug.
Supportive ifManagement shares a Phase 3 design, including the planned trial and timing, by March 2027.
Worry ifManagement has not set a Phase 3 design by March 2027, or says the data do not support further study.
Why it matters: This is the key test of whether Halneuron eases chemotherapy-related nerve pain. The trial has 239 patients and a week-four pain score endpoint.
Watch forThe November results meet the main goal. Pain scores improve by a significant amount versus placebo.
Also watch forThe trial misses its main goal, or the company reports no clear pain-score benefit versus placebo.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$301 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $1,002 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,490 loss on $10,000 · 84.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.